Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Biomarker Research

Fig. 4

From: Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-γ2 as a promising diagnostic tool of non-muscle invasive bladder cancer

Fig. 4

Receiver operating characteristic (ROC) curve analysis. a Bladder cancer (BC) vs. benign urological disease and healthy donors (HDs), (b) BC vs. HDs, (c) non-muscle invasive BC (NMIBC; ≤pT1) and muscle invasive BC (MIBC; ≥pT2) vs. HDs, (d) NMIBC vs. HDs, and (e) MIBC vs. HDs. The area under the curve (AUC) value for BC vs. benign disease and HDs (a) was 0.87, and the AUC value for BC vs. HDs (b) was 0.81. These AUC values are sufficient to facilitate a diagnosis of BC. The AUC values for NMIBC and MIBC (c), NMIBC (d), and MIBC (e) were all 0.86. Thus, mono-Ln-γ2 in urine can be used to diagnose both NMIBC and MIBC

Back to article page